American Journal of Cardiology
Volume 103, Issue 9 , Pages 1255-1260 , 1 May 2009

Relation of Plasma Midregional Proatrial Natriuretic Peptide to Target Organ Damage in Adults With Systemic Hypertension

  • Mahyar Khaleghi, MD

      Affiliations

    • Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota
    • ,
  • Malik A. Al-Omari, MD

      Affiliations

    • Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota
    • ,
  • Venkateswarlu Kondragunta, PhD

      Affiliations

    • Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota
    • ,
  • Nils G. Morgenthaler, MD

      Affiliations

    • Research Department, BRAHMS Aktiengesellschaft, Hennigsdorf, Germany
    • ,
  • Joachim Struck, PhD

      Affiliations

    • Research Department, BRAHMS Aktiengesellschaft, Hennigsdorf, Germany
    • ,
  • Andreas Bergmann, PhD

      Affiliations

    • Research Department, BRAHMS Aktiengesellschaft, Hennigsdorf, Germany
    • ,
  • Thomas H. Mosley, MD

      Affiliations

    • Department of Medicine (Geriatrics), University of Mississippi Medical Center, Jackson, Mississippi
    • ,
  • Iftikhar J. Kullo, MD

      Affiliations

    • Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota
    • Corresponding Author InformationCorresponding author: Tel: 507-266-3964; fax: 507-266-1617

Received 25 November 2008 ,Revised 5 January 2009 ,Accepted 5 January 2009.

References 

  1. Vesely DL. Atrial natriuretic peptide prohormone gene expression: hormones and diseases that upregulate its expression. IUBMB Life. 2002;53:153–159
  2. Ala-Kopsala M, Magga J, Peuhkurinen K, Leipala J, Ruskoaho H, Leppaluoto J, et al. Molecular heterogeneity has a major impact on the measurement of circulating N-terminal fragments of A- and B-type natriuretic peptides. Clin Chem. 2004;50:1576–1588
  3. Morgenthaler NG, Struck J, Thomas B, Bergmann A. Immunoluminometric assay for the midregion of pro-atrial natriuretic peptide in human plasma. Clin Chem. 2004;50:234–236
  4. Khaleghi M, Saleem U, Morgenthaler NG, Turner ST, Bergmann A, Struck J, et al. Plasma midregional pro-atrial natriuretic peptide is associated with blood pressure indices and hypertension severity in adults with hypertension. Am J Hypertens. 2009;(Epub ahead of print). doi: 10.1038/ajh.2009.8
  5. Granger CB, Van Eyk JE, Mockrin SC, Anderson NL. National Heart, Lung, and Blood Institute clinical proteomics working group report. Circulation. 2004;109:1697–1703
  6. O'Meara JG, Kardia SL, Armon JJ, Brown CA, Boerwinkle E, Turner ST. Ethnic and sex differences in the prevalence, treatment, and control of dyslipidemia among hypertensive adults in the GENOA study. Arch Intern Med. 2004;164:1313–1318
  7. Ellington AA, Malik AR, Klee GG, Turner ST, Rule AD, Mosley TH, et al. Association of plasma resistin with glomerular filtration rate and albuminuria in hypertensive adults. Hypertension. 2007;50:708–714
  8. Hiatt WR. Medical treatment of peripheral arterial disease and claudication. N Engl J Med. 2001;344:1608–1621
  9. Skelton TN, Andrew ME, Arnett DK, Burchfiel CM, Garrison RJ, Samdarshi TE, et al. Echocardiographic left ventricular mass in African-Americans: the Jackson cohort of the Atherosclerosis Risk in Communities Study. Echocardiography. 2003;20:111–120
  10. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol. 1986;57:450–458
  11. de Simone G, Daniels SR, Devereux RB, Meyer RA, Roman MJ, de Divitiis O, et al. Left ventricular mass and body size in normotensive children and adults: assessment of allometric relations and impact of overweight. J Am Coll Cardiol. 1992;20:1251–1260
  12. Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics. 1986;42:121–130
  13. Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Gattobigio R, Zampi I, et al. Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation. 1998;97:48–54
  14. Vasan RS, Benjamin EJ, Larson MG, Leip EP, Wang TJ, Wilson PW, et al. Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: the Framingham heart study. JAMA. 2002;288:1252–1259
  15. Schirmer H, Omland T. Circulating N-terminal pro-atrial natriuretic peptide is an independent predictor of left ventricular hypertrophy in the general population (The Tromso Study). Eur Heart J. 1999;20:755–763
  16. Kinnunen P, Vuolteenaho O, Ruskoaho H. Mechanisms of atrial and brain natriuretic peptide release from rat ventricular myocardium: effect of stretching. Endocrinology. 1993;132:1961–1970
  17. Omland T, Aakvaag A, Vik-Mo H. Plasma cardiac natriuretic peptide determination as a screening test for the detection of patients with mild left ventricular impairment. Heart. 1996;76:232–237
  18. Pedrinelli R, Dell'Omo G, Di Bello V, Pontremoli R, Mariani M. Microalbuminuria, an integrated marker of cardiovascular risk in essential hypertension. J Hum Hypertens. 2002;16:79–89
  19. Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, et al Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA. 2001;286:421–426
  20. Rosa TT, Palatini P. Clinical value of microalbuminuria in hypertension. J Hypertens. 2000;18:645–654
  21. Russo LM, Bakris GL, Comper WD. Renal handling of albumin: a critical review of basic concepts and perspective. Am J Kidney Dis. 2002;39:899–919
  22. Awazu M, Ichikawa I. Biological significance of atrial natriuretic peptide in the kidney. Nephron. 1993;63:1–14
  23. Zietse R, Derkx FH, Weimar W, Schalekamp MA. Effect of atrial natriuretic peptide on renal and vascular permeability in diabetes mellitus. J Am Soc Nephrol. 1995;5:2057–2066
  24. Vervoort G, Wetzels JF, Lutterman JA, Bravenboer B, Berden JH, Smits P. Atrial natriuretic peptide-induced microalbuminuria is associated with endothelial dysfunction in noncomplicated type 1 diabetes patients. Am J Kidney Dis. 2002;40:9–15
  25. Kullo IJ, Bailey KR, Kardia SL, Mosley TH, Boerwinkle E, Turner ST. Ethnic differences in peripheral arterial disease in the NHLBI Genetic Epidemiology Network of Arteriopathy (GENOA) study. Vasc Med. 2003;8:237–242
  26. Kuller L, Fisher L, McClelland R, Fried L, Cushman M, Jackson S, et al. Differences in prevalence of and risk factors for subclinical vascular disease among black and white participants in the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol. 1998;18:283–293
  27. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med. 1998;339:321–328
  28. Kook H, Itoh H, Choi BS, Sawada N, Doi K, Hwang TJ, et al. Physiological concentration of atrial natriuretic peptide induces endothelial regeneration in vitro. Am J Physiol Heart Circ Physiol. 2003;284:H1388–H1397
  29. Molkentin JD. A friend within the heart: natriuretic peptide receptor signaling. J Clin Invest. 2003;111:1275–1277

 This work was supported by Grant HL-81331 from the National Institutes of Health, Bethesda, Maryland.

 Dr. Morganthaler, Dr. Struck, and Dr. Bergmann are employed by BRAHMS AG, which developed the assay used for the measurement of MR-proANP in this study.

PII: S0002-9149(09)00104-0

doi: 10.1016/j.amjcard.2009.01.012

American Journal of Cardiology
Volume 103, Issue 9 , Pages 1255-1260 , 1 May 2009

Article Tools

* Image Usage & Resolution